Our customers rely on our industry-leading data and insights and cutting-edge technology to overcome barriers to access.LEARN MORE
Let our unbeatable covered lives methodology and innovative technology inform your market access strategy.LEARN MORE
Establish reimbursement policies, formulary positioning and access financial assistance that make therapies affordable for patients.LEARN MORE
Quickly analyze and visualize real-world patient datasets to instantly obtain answers to access barriers and prescribing patterns.LEARN MORE
Four leading specialty pharmacies honored for their dedication to the highest quality customer service.
MMIT offers a range of publications for pharma, payers and providers covering news, strategy and insights across the spectrum. Our in-house journalism division AIS Health provides objective news and analysis of industry trends while RJ Health provides a comprehensive look at industry updates as they apply to medically covered drug reimbursement processes.
In competitive therapeutic areas, like immunology and oncology, optimizing market share depends on creating a more structured, holistic market access story.
Biotech and pharma companies have a vast range of capabilities and data sophistication, from their data acquisition strategy down to the way they consume, curate and present data internally.
The COVID-19 pandemic illuminated a challenge to the U.S. healthcare system that continues to undermine effective patient care: medication shortages.
Welcome back to our Market Access 101 blog series, which began with the basics of market access and covered how to improve formulary placement and secure coverage under the medical benefit.
While the Inflation Reduction Act (IRA) may best be known for mandating Medicare drug price negotiation, the act did much more than that.
The rising cost of specialty pharmaceuticals has motivated payers to implement tighter restrictions and seek both traditional and value-based contracts.
Get the latest from MMIT’s leading subject matter experts, receiving the latest posts right to your inbox. Top-quality thought leadership 100% free.